Trial · NCT02018042
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
NCT02018042, Phase 2, Completed, Columbia University; results first posted 2019-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata. Trials, record NCT02018042. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02018042
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
- NCT number
- NCT02018042
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Alopecia Areata
- Interventions
- Abatacept
- First posted
- 2013-12-23
- Last updated
- 2019-04-30
- Results first posted
- 2019-04-17
- Limitations and caveats
Small study size and potential for spontaneous remission that might discount the validity of clinical response. A greater observational post treatment period would strengthen conclusions. Last, inherent observer bias, by SALT scoring \& photography.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Participants With At Least 50% Hair Regrowth | Week 24 | The study's primary efficacy endpoint will be the proportion of responders after 6 months of treatment, with response defined as 50% or greater hair re-growth from baseline as assessed by Severity of Alopecia Tool (SALT) score at week 24. This is a relatively strict definition for defining responders and non-responders and was chosen to minimize the potential for spontaneous remission, in which fewer than 10% are expected to achieve this magnitude of hair regrowth spontaneously. |
| Secondary | Percentage of Hair Regrowth | Week 24 | Percent hair regrowth from baseline determined by global overall improvement in SALT measurements following 24 weeks of treatment. |
| Secondary | Measurement of Quality of Life | Baseline, Week 12, Week 24 | Quality of life measures were based on changes in the Dermatology Life Quality Index (DLQI). The DLQi is a 10-item questionnaire with each question scored from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0 (better outcome). The higher the score, the more quality of life is impaired. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Participants With At Least 50% Hair Regrowth | Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Hair Regrowth | Week 24 | percentage | MEAN | |
| SECONDARY | Measurement of Quality of Life | Baseline, Week 12, Week 24 | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Participants With At Least 50% Hair Regrowth | Abatacept | 1 | Participants | ||
| Percentage of Hair Regrowth | Abatacept | 21.3 | Full Range 2.9 to 91 | percentage | |
| Measurement of Quality of Life | Abatacept | Baseline | 4.2 | Standard Deviation 3.8 | score on a scale |
| Measurement of Quality of Life | Abatacept | Week 12 | 3.9 | Standard Deviation 3.8 | score on a scale |
| Measurement of Quality of Life | Abatacept | Week 24 | 4.6 | Standard Deviation 3.8 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Abatacept | 15 | |
| Overall Study | COMPLETED | Abatacept | 14 | |
| Overall Study | NOT COMPLETED | Abatacept | 1 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Infection | Respiratory, thoracic and mediastinal disorders | Abatacept | 6 | 15 | |
| other | Site Injection | Product Issues | Abatacept | 3 | 15 | |
| other | Candidiasis/Yeast Infection | Reproductive system and breast disorders | Abatacept | 1 | 15 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Abatacept | 0 | 15 |
| Total, other adverse events | Abatacept | 6 | 15 |
| Total, serious adverse events | Abatacept | 0 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25676427 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02018042
GET https://conductscience.org/api/trials/v1/NCT02018042/registered